Larotreni (Larotrectinib) 25mg/100mg×60 Capsules | TLPH Laos NTRK Fusion | GLT

Generic Information: Larotreni (Larotrectinib) — TLPH (Tongmeng), Laos

Larotreni is the larotrectinib capsule of Tongmeng (Lao) Pharmaceutical and Food Co., Ltd., the manufacturer known as TLPH — one of Laos' most export-active producers and, alongside its entrectinib, a maker of two tissue-agnostic TRK-family inhibitors. The Lao Food and Drug Department approved Larotreni in August 2022 in two strengths, 25 mg and 100 mg, each in a 60-capsule bottle. The two-strength design supports both the standard 100 mg twice-daily dose and the 75 mg and 50 mg reduction steps, making it one of the more complete generic ranges for this molecule.

What Is Larotreni (Larotrectinib) Used For?

Larotreni treats adult and pediatric patients with solid tumors that carry a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, where disease is metastatic or surgery would likely cause severe morbidity, and where there is no satisfactory alternative or the cancer has progressed after treatment. The fusion-based indication spans infantile fibrosarcoma, salivary gland tumors, soft-tissue sarcoma, thyroid cancer, lung cancer and other NTRK fusion-positive solid tumors once testing confirms the fusion.

How Does Larotreni (Larotrectinib) Work?

The active ingredient is a selective, ATP-competitive inhibitor of the tropomyosin receptor kinase (TRK) family — TRKA, TRKB and TRKC, encoded by NTRK1, NTRK2 and NTRK3. An NTRK fusion creates a constitutively active TRK fusion protein that drives tumor growth; blocking all three TRK kinases removes that driver and shrinks tumors across tissues. Larotreni uses the same sulfate salt formulation as the originator, delivered in hard gelatin capsules.

Indications of Larotreni (Lao Label)

The Lao label mirrors the originator's tissue-agnostic scope: NTRK fusion-positive solid tumors without acquired resistance, locally advanced or metastatic or high-risk-for-surgery, and no satisfactory alternative or progression after prior therapy. TLPH's own patient information follows the same selection rule as the originator — the fusion must be confirmed by a validated test, because the drug has minimal activity against fusion-negative tumors and against acquired TRK resistance mutations.

Dosage and Administration

The standard dose is 100 mg orally twice daily for adults and children with body surface area of at least 1.0 m², with or without food, until progression or unacceptable toxicity; children below 1.0 m² receive 100 mg/m² twice daily. The 25 mg capsule supports dose reductions — 75 mg twice daily as a 25 mg plus 50 mg, and 50 mg twice daily as two 25 mg capsules. Capsules are swallowed whole, and a missed dose within six hours of the next is skipped rather than doubled.

Side Effects of Larotreni

Expect the class profile: fatigue, nausea, dizziness, vomiting, cough, constipation, diarrhea and raised AST and ALT in at least 20% of patients. Neurotoxicity — dizziness, cognitive changes, mood and sleep disturbance — calls for caution with driving and machinery, and hepatotoxicity is managed with liver-function monitoring every two weeks early on and monthly thereafter. Skeletal fractures warrant prompt evaluation, and effective contraception is required during and for one week after treatment.

Storage Instructions

Store the 60-capsule bottles at room temperature in a closed container protected from moisture, out of children's reach. TLPH stock ships with the Lao FDD approval and a batch number, giving buyers a verifiable provenance for a generic sourced from Vientiane.

Why Choose Larotreni from GLT?

Larotreni is the two-strength Laos option for buyers who want 25 mg and 100 mg capsules for flexible dosing from a manufacturer that also makes the related TRK inhibitor entrectinib. GLT quotes it beside the originator Vitrakvi and the other generics (Laronib, Tractoni, LuciLaro, Larodx) so the full NTRK price ladder is visible before a decision. Sealed stock with pre-shipment photographs and export documentation comes standard, and a real person answers on WhatsApp +86 15234153837 or at [email protected].

How to Order Larotreni (Larotrectinib)

Message GLT on WhatsApp +86 15234153837 or write to [email protected] with the strength, bottle quantity and destination. A formal quotation with courier and payment options returns within a working day, and recurring supply can be scheduled for continuous therapy. Confirmed orders ship sealed with complete export paperwork.

FAQ

Why two strengths? The 100 mg capsule is the standard dose; the 25 mg capsule supports the 75 mg and 50 mg dose-reduction steps.

Who makes Larotreni? Tongmeng (Lao) Pharmaceutical and Food Co., Ltd., known as TLPH, approved by the Lao FDD in August 2022.

Is it the same as Vitrakvi? Same active ingredient and dose; Larotreni is the TLPH Laos generic.

Does it need a gene test? Yes — NTRK fusion must be confirmed before treatment.

Can children take it? Yes, with body-surface-area-based dosing.